{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:21:49Z","timestamp":1787775709895,"version":"build-2784847793"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) serve as pivotal tumor markers in colorectal cancer (CRC). However, uncertainty persists regarding the prognostic significance of the two tumor markers when falling within the normal range. We attempt to compare the prognostic differences of tumor markers at different levels within the reference range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study scrutinized 2,167 cases of stage II CRC verified by pathology after surgery at the Fudan University Shanghai Cancer Center. Using R software to calculate the optimal critical value to compare the clinical and pathological characteristics and prognosis of different levels of tumor markers. The survival and regression modeling strategies packages of R software drew the nomograms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Utilizing R software, the optimal critical value of CA19-9 was determined as 12.12 U\/mL and that of CEA as 1.89 U\/mL. Kaplan-Meier survival analysis unveiled that, within the normal range, higher levels of CEA were linked to poorer overall survival (OS) [HR = 1.829 (1.280, 2.989),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0033] and disease-free survival (DFS) [HR = 1.472 (1.114, 1.944),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0444]. Similarly, heightened levels of CA19-9 also indicated inferior OS [HR = 1.750 (1.203, 2.455),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0076] and DFS [HR = 1.361 (1.098, 1.686),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0049]. Furthermore, multivariate analysis identified CA19-9 as an independent risk factor for OS (HR = 1.49,95% CI: 1.086\u20132.045,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014) and DFS (HR = 1.327,95% CI: 1.070\u20131.647,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), while the impact of CEA on OS and DFS was not statistically significant. A nomogram constructed based on the Cox regression model can effectively evaluate the prognosis of CRC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although within the normal range, elevated CA19-9 was associated with an inferior prognosis, chemotherapy decisions of different intensities can be adjusted based on nomograms. This work will contribute to standardizing the diagnosis and treatment of stage II CRC and provide clinicians with essential insights for chemotherapy decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_338_24","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:02:33Z","timestamp":1736510553000},"page":"2013-2020","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Elevated CA19-9 within the normal range suggests poorer prognosis in stage II CRC: A retrospective analysis of a large sample in a single center"],"prefix":"10.4103","volume":"20","author":[{"given":"Ruoxin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Shanghai Cancer Center, Fudan University, Xuhui District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Shanghai Cancer Center, Fudan University, Xuhui District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyong","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Shanghai Cancer Center, Fudan University, Xuhui District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Shanghai Cancer Center, Fudan University, Xuhui District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Shanghai Cancer Center, Fudan University, Xuhui District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"R1-20250110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020:GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/gastro\/goab010","article-title":"Gastrointestinal cancers in China, the USA, and Europe","volume":"9","author":"Xie","year":"2021","journal-title":"Gastroenterology Rep"},{"key":"R3-20250110","first-page":"255","article-title":"Incidence, mortality, survival, risk factor and screening of colorectal cancer:A comparison among China, Europe, and northern America Cancer lett","volume":"522","author":"Li","year":"2021"},{"key":"R4-20250110","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00432-018-2795-1","article-title":"Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)","volume":"145","author":"Xu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R5-20250110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R6-20250110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.21147\/j.issn.1000-9604.2019.01.07","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"R7-20250110","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1245\/s10434-009-0625-z","article-title":"Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer:Clinical significance of the preoperative level","volume":"16","author":"Park","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R8-20250110","first-page":"3753","article-title":"Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer","volume":"34","author":"Shibutani","year":"2014","journal-title":"Anticancer Res"},{"key":"R9-20250110","doi-asserted-by":"crossref","first-page":"758509","DOI":"10.3389\/fonc.2021.758509","article-title":"Early Postoperative serum carcinoembryonic antigen is a stronger independent prognostic factor for stage II colorectal cancer patients than T4 stage and preoperative CEA","volume":"11","author":"Fenqi","year":"2021","journal-title":"Front Oncol"},{"key":"R10-20250110","first-page":"914","article-title":"[Predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage II-III colorectal cancer","volume":"18","author":"Chen","year":"2015","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"R11-20250110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.01.112","article-title":"Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer","volume":"94","author":"Margalit","year":"2018","journal-title":"Eur J Cancer (Oxford, England:1990)"},{"key":"R12-20250110","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann oncol"},{"key":"R13-20250110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(05)17706-X","article-title":"Colorectal cancer","volume":"365","author":"Weitz","year":"2005","journal-title":"Lancet (London, England)"},{"key":"R14-20250110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jso.21914","article-title":"High-risk stage II colon cancer after curative resection","volume":"104","author":"Sato","year":"2011","journal-title":"J Surg Oncol"},{"key":"R15-20250110","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4103\/jcrt.JCRT_1248_21","article-title":"Translational cancer research in India:Challenges and Promises","volume":"19","author":"Gandhi","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R16-20250110","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.21873\/anticanres.13857","article-title":"Microsatellite instability and survival in stage II colorectal cancer:A systematic review and meta-analysis","volume":"39","author":"Petrelli","year":"2019","journal-title":"Anticancer Res"},{"key":"R17-20250110","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer:A randomised study","volume":"370","author":"Gray","year":"2007","journal-title":"Lancet (London, England)"},{"key":"R18-20250110","first-page":"5","article-title":"Risk of recurrence in patients with colon cancer stage II and III:A systematic review and meta-analysis of recent literature Acta Oncol (Stockholm, Sweden)","volume":"54","author":"B\u00f6ckelman","year":"2015"},{"key":"R19-20250110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12885-023-11093-w","article-title":"Risk factors for postoperative recurrence in patients with stage II colorectal cancer","volume":"23","author":"Xiong","year":"2023","journal-title":"BMC Cancer"},{"key":"R20-20250110","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00432-016-2208-2","article-title":"High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer","volume":"142","author":"Park","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"R21-20250110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijsu.2016.08.528","article-title":"Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer:A retrospective cohort study","volume":"37","author":"Al-Sukhni","year":"2017","journal-title":"Int J Surg (London, England)"},{"key":"R22-20250110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101567","article-title":"Microsatellite instability:Diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer","volume":"11","author":"Evrard","year":"2019","journal-title":"Cancers"},{"key":"R23-20250110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer:Diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer (Oxford, England:1990)"},{"key":"R24-20250110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4103\/jcrt.jcrt_792_22","article-title":"Cisplatin-based combination therapy for cancer","volume":"19","author":"Minerva","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R25-20250110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family:Structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"R26-20250110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ueg2.12449","article-title":"Monitoring Ca19-9 during pancreatic cyst surveillance:Better safe than sorry?","volume":"11","author":"Perri","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"R27-20250110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3393\/ac.2019.11.13","article-title":"A review of the role of carcinoembryonic antigen in clinical practice","volume":"35","author":"Hall","year":"2019","journal-title":"Ann Coloproctol"},{"key":"R28-20250110","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.31900","article-title":"CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer:A prospective evaluation","volume":"144","author":"Honda","year":"2019","journal-title":"Int J Cancer"},{"key":"R29-20250110","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1038\/s41598-018-21048-y","article-title":"Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"key":"R30-20250110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/oxfordjournals.annonc.a059248","article-title":"The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer","volume":"6","author":"Webb","year":"1995","journal-title":"Ann Oncol"},{"key":"R31-20250110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21873\/anticanres.11329","article-title":"Clinical performance of CEA, CA19-9, CA15-3, CA125 and AFP in gastrointestinal cancer using LOCI\u2122-based assays","volume":"37","author":"Dolscheid-Pommerich","year":"2017","journal-title":"Anticancer Res"},{"key":"R32-20250110","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4103\/jcrt.jcrt_1184_22","article-title":"Colorectal cancer and dostarlimab-An episode in discovery to new era of immunotherapy","volume":"19","author":"Bethineedi","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R33-20250110","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00384-012-1447-1","article-title":"Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis","volume":"27","author":"Lin","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"R34-20250110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4174\/astr.2019.96.3.107","article-title":"High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis","volume":"96","author":"Shin","year":"2019","journal-title":"Ann Surg Treatment Res"},{"key":"R35-20250110","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00432-013-1459-4","article-title":"Factors predicting long-term survival in colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen","volume":"139","author":"Huh","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"R36-20250110","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1245\/s10434-020-08256-5","article-title":"Clinical significance of preoperative serum carcinoembryonic antigen within the normal range in colorectal cancer patients undergoing curative resection","volume":"27","author":"Beom","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R37-20250110","doi-asserted-by":"crossref","first-page":"22830","DOI":"10.1038\/s41598-023-49832-5","article-title":"Prognostic value of normal levels of preoperative tumor markers in colorectal cancer","volume":"13","author":"Ren","year":"2023","journal-title":"Sci Rep"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_338_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:39:29Z","timestamp":1787773169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_338_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_338_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}